• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form PX14A6G filed by Centene Corporation

    4/11/25 2:27:04 PM ET
    $CNC
    Medical Specialities
    Health Care
    Get the next $CNC alert in real time by email
    PX14A6G 1 i411251px14a6g.htm

     

     

     

     

     

    Notice of Exempt Solicitation Pursuant to Rule 14a-103

    Name of Registrant: Centene Corporation (CNC)

    Name of person relying on exemption: John Chevedden, Centene Shareholder since 2019

    Address of persons relying on exemption: POB 2673, Redondo Beach, CA 90278

     

    These written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. John Chevedden does not beneficially own more than $5 million of the class of subject securities, and this notice of exempt solicitation is therefore being provided on a voluntary basis.

     

    This is not a solicitation of authority to vote your proxy.

     

    Please DO NOT send me your proxy card; the shareholder is not able to vote your proxies, nor does this communication contemplate such an event.

     

    The shareholder asks all shareholders to vote by following the procedural instructions provided in the proxy materials. 

     

     

     

    Please Support Item #5 to Disclose Plan to Reduce Total Contribution to Climate Change

     

    To Centene Shareholders:

     

    I ask shareholders to vote FOR Item 5 at the Centene shareholder meeting on May 13, 2025. The proposal asks Centene (“the Company”) to disclose a report on its plans for reducing its contribution to climate change:

     

    RESOLVED: Shareholders request that Centene issue a report (at reasonable cost, omitting proprietary information) describing if, and how, it plans to reduce its total contribution to climate change and align its operations and investments with the Paris Agreement’s ambition of limiting global temperature rise.

     

    SUPPORTING STATEMENT: In the report shareholders seek information, at board and management discretion, on the relative benefits and drawbacks of integrating the following actions:

     

    ·Adopting science-based GHG emission reduction targets for the Company's full range of operational and value chain emissions, taking into consideration criteria used by advisory groups like the Science Based Targets initiative;

     

      
     

     

    ·Developing a transition plan that shows how the Company plans to meet its goals, taking into consideration criteria used by advisory groups such as the Transition Plan Taskforce, Task Force for Climate-Related Financial Disclosures, CDP, Climate Action 100+, and Ceres; and
    ·Adopting supporting targets for renewable energy, energy efficiency, supply chain engagement, or other measures deemed appropriate by management.

     

    1.Centene acknowledges that climate change poses risks to its business.

     

    In order to limit warming to 1.5 °C and prevent the worst impacts of climate change, emissions must be cut in half by 2030 and reach net zero by 2050. Rising temperatures associated with climate change not only increase the frequency of extreme weather events, which may pose physical risks to Centene’s operations, but also exacerbate health hazards by worsening air quality,1 augmenting heat-related illnesses,2 and spreading vector-borne diseases.3 Centene has analyzed various climate drivers and identified a myriad of negative health outcomes that may arise from them, which could impact the Company’s margins as global temperatures continue to increase.4 Indeed, Centene notes in its most recent 10-K that the effects of climate change “could reduce our ability to accurately predict and effectively control the costs of providing health benefits.”5 The Company’s opposition statement identifies the “increasing regulatory and political uncertainty regarding disclosure and management of climate-related risks” as a reason to vote against this proposal. However, these changing dynamics do not affect the imperative to mitigate the material financial risks that climate change poses to Centene’s business, investor portfolios, and the global economy.

     

    2.Centene does not have a long-term climate mitigation strategy aligned with the Paris Agreement’s ambition to limit warming to 1.5 °C, and this proposal provides the Company with flexibility in its approach.

     

    While Centene’s emissions reduction efforts to date are commendable, the Company has not set targets for continuing progress in the near term or reaching net zero in the long term. Setting forward-looking goals is especially relevant as a large portion of the Company’s scope 1 and 2 reductions appear to have resulted from its reduced real estate footprint. While this created reductions in the Company’s emissions accounting, it is unclear whether Centene’s emissions have declined per square foot across its remaining real estate footprint or whether this action translated to fewer real-world emissions. Furthermore, over 80% of Centene’s emissions fall into scope 3, purchased goods and services, for which the Company has not described any efforts to reduce its supply chain emissions. Additional progress may require actions such as renewable energy procurement and supply chain engagement, which require careful planning and dedication of resources. Both these actions could, as examples, result in lower energy costs, increased resilience, and strengthened supplier relationships for the Company.

    _____________________________

    1 https://www.epa.gov/climateimpacts/climate-change-impacts-air-quality

    2 https://www.nejm.org/doi/full/10.1056/NEJMra2210769

    3 https://www.cdc.gov/climate-health/php/effects/vectors.html

    4 https://www.centene.com/content/dam/centenedotcom/documents/TCFD-Index-2024.pdf

    5 https://www.sec.gov/ix?doc=/Archives/edgar/data/1071739/000107173924000037/cnc-20231231.htm

     

      
     

     

     

    The proponent supports the Company’s desire to maintain “flexibility to choose from among appropriate sustainability initiatives and the timing for the implementation of those initiatives," as expressed in the opposition statement. This proposal does not seek to prescribe specific emissions reduction strategies or impose a particular timeline for setting targets, providing latitude to the Company regarding implementation. Rather, the proposal seeks a report to understand if, and how, Centene will continue to reduce its climate impacts and mitigate associated risks going forward.

     

    3.The Company lags peers in setting GHG reduction targets.

     

    Industry peers have high ambitions for GHG reduction. CVS Health (Aetna) and UnitedHealth Group have set and committed to set, respectively, both near-term and net zero targets through the Science Based Targets initiative (SBTi). Cigna also committed to set near-term targets through the SBTi this past summer.6 Elevance Health aims to achieve net zero by 2050 and notes, “we engage our top 80% of suppliers by spend on setting their own science-based emissions reduction targets.” Elevance Health is a signatory to RE100, a corporate renewable energy initiative, and has used 100% renewable energy to power its operations since 2021, 4 years ahead of its 2025 target year.7 The proposal recommends that Centene assess setting targets through the SBTi, which would provide the Company a full two years after making the initial commitment to set targets and identify appropriate strategies to achieve them.

     

     

    Vote “Yes” on Shareholder Proposal #5

     

    _____________________________

    6 https://sciencebasedtargets.org/target-dashboard

    7 https://www.elevancehealth.com/content/dam/elevance-health/documents/ELV_2023_Impact_Report.pdf

     

     

     

     

     

     

    Get the next $CNC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNC

    DatePrice TargetRatingAnalyst
    4/8/2025$64.00Underperform → Hold
    Jefferies
    2/6/2025Buy → Hold
    Argus
    12/17/2024$80.00 → $75.00Overweight
    Analyst
    12/13/2024$79.00 → $80.00Neutral → Buy
    UBS
    12/10/2024$68.00 → $52.00Hold → Underperform
    Jefferies
    7/24/2024$83.00 → $69.00Buy → Hold
    Jefferies
    5/30/2024$83.00Neutral
    Robert W. Baird
    3/21/2024$92.00 → $85.00Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $CNC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NVA Appoints Ken Burdick Executive Chairman Ahead of Future IPO

      Board further strengthened with appointment of Mike McFarland as Director National Veterinary Associates Group ("NVA"), a leading veterinary care organization, today announced it has strengthened its Board with the appointments of Ken Burdick as Executive Chairman and Dr. James "Mike" McFarland as Director. These executives bring substantial healthcare and public company experience ahead of the company's future IPO. Burdick is a seasoned public company executive with more than 40 years of healthcare experience. He currently serves as Executive Chairman at LifeStance Health (NASDAQ:LFST), a leading U.S. provider of outpatient mental healthcare. Since joining LifeStance as Chairman and CEO

      5/7/25 2:00:00 PM ET
      $CNC
      $LFST
      Medical Specialities
      Health Care
      Medical/Nursing Services
    • CENTENE SUBSIDIARY ARIZONA COMPLETE HEALTH JOINS SETTLEMENT AGREEMENT TO MOVE FORWARD WITH STATEWIDE LONG-TERM CARE MEDICAID CONTRACT

      ST. LOUIS, May 2, 2025 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its subsidiary, Arizona Complete Health, the largest Medicaid health plan in Arizona, has joined the Arizona Health Care Cost Containment System (AHCCCS) – Arizona's single state Medicaid agency – and three other health plans in reaching a settlement agreement to provide managed care for the Arizona Long Term Care System (ALTCS). The ALTCS program supports nearly 26,000 Arizonans who are elderly and/or have a physical disability (EPD) with physical and behavioral healthcare, as well as pharmacy benefits and home- and co

      5/2/25 7:05:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Oklahoma Complete Health Offers New and Upgraded Benefits for SoonerSelect Members in 2025

      OKLAHOMA CITY, May 1, 2025 /PRNewswire/ -- Oklahoma Complete Health introduces new and upgraded SoonerSelect benefits to support members. Enhancements to the value-added services aim to improve health outcomes and overall well-being of members. "Oklahoma Complete Health is excited to expand the 2025 offerings to serve our members," said Oklahoma Complete Health's President and CEO Clay Franklin. "Our plan continues to prioritize the health and well-being of Oklahomans and find ways to meet their unique needs." New and upgraded benefits include: New: Diaper ClubStarting July 1,

      5/1/25 9:06:00 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Centene Corporation

      SC 13G - CENTENE CORP (0001071739) (Subject)

      11/14/24 4:06:01 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centene Corporation

      SC 13G/A - CENTENE CORP (0001071739) (Subject)

      11/13/24 3:02:23 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centene Corporation

      SC 13G/A - CENTENE CORP (0001071739) (Subject)

      11/12/24 9:55:15 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Greco Thomas bought $1,015,750 worth of shares (17,000 units at $59.75), increasing direct ownership by 736% to 19,309 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      12/19/24 5:39:30 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Director Dallas H James bought $99,904 worth of shares (1,693 units at $59.01) (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      12/17/24 7:34:06 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Director Blume Jessica L. bought $14,870 worth of shares (250 units at $59.48) (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      12/17/24 7:33:56 PM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Leadership Updates

    Live Leadership Updates

    See more
    • NVA Appoints Ken Burdick Executive Chairman Ahead of Future IPO

      Board further strengthened with appointment of Mike McFarland as Director National Veterinary Associates Group ("NVA"), a leading veterinary care organization, today announced it has strengthened its Board with the appointments of Ken Burdick as Executive Chairman and Dr. James "Mike" McFarland as Director. These executives bring substantial healthcare and public company experience ahead of the company's future IPO. Burdick is a seasoned public company executive with more than 40 years of healthcare experience. He currently serves as Executive Chairman at LifeStance Health (NASDAQ:LFST), a leading U.S. provider of outpatient mental healthcare. Since joining LifeStance as Chairman and CEO

      5/7/25 2:00:00 PM ET
      $CNC
      $LFST
      Medical Specialities
      Health Care
      Medical/Nursing Services
    • CENTENE APPOINTS KENNETH Y. TANJI TO BOARD OF DIRECTORS

      ST. LOUIS, Feb. 24, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today the appointment of Kenneth Y. Tanji to the Centene Board of Directors, effective February 20, 2025. Mr. Tanji will serve on the Company's Audit and Compliance Committee. The appointment of Mr. Tanji expands Centene's Board of Directors to 12 members. Mr. Tanji's finance acumen spans more than three decades and includes deep knowledge of capital optimization strategies, strategic acquisitions, JV partnership models and the use of advanced analytics and technologies to scale g

      2/24/25 4:15:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene Corporation Names First President over Individual Coverage Health Reimbursement Arrangements (ICHRA) Business

      New leadership role reflects Centene's focus on ICHRA growth ST LOUIS, Jan. 9, 2025 /PRNewswire/ -- Centene Corporation ("Centene") (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, is pleased to announce that Alan Silver has joined the organization as the President of its Ambetter Health Solutions business, which focuses on ICHRA (Individual Coverage Health Reimbursement Arrangements). This newly created role reflects Centene's belief that consumers increasingly will seek health insurance that offers transparency, customization, choice and convenience. ICHRA plans allow employees to shop on the individual Marketplace and choose the insurance plan

      1/9/25 9:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Financials

    Live finance-specific insights

    See more
    • CENTENE CORPORATION REPORTS FIRST QUARTER 2025 RESULTS

      -- Diluted EPS of $2.63; Adjusted Diluted EPS of $2.90 -- First quarter 2025 adjusted diluted EPS of $2.90, up 28% from $2.26 in the first quarter of 2024.17% year-over-year premium and service revenue growth.Membership increases of 29% in Marketplace and 22% in Medicare PDP, compared to the first quarter of 2024.Increased 2025 premium and service revenues guidance by $6.0 billion driven by outperformance in Marketplace enrollment and Medicare member retention.ST. LOUIS, April 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the first quarter ended March 31, 2025. In summary, the 2025 first quarter results were as follows: Total

      4/25/25 6:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care
    • CENTENE CORPORATION TO HOST 2025 FIRST QUARTER FINANCIAL RESULTS EARNINGS CALL

      ST. LOUIS, March 18, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 first quarter financial results at approximately 6:00 a.m. ET on Friday, April 25, 2025, and host a conference call at 8:30 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 9776439 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com, under the Investors

      3/18/25 4:53:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • CENTENE CORPORATION REPORTS 2024 RESULTS

      -- 2024 Full Year Diluted EPS of $6.31; Adjusted Diluted EPS of $7.17 -- 2024 adjusted diluted EPS of $7.17, up 7% from $6.68 in 2023.Membership increases of 12% in Marketplace and 50% in Medicare PDP, compared to the fourth quarter of 2023.Executed on capital deployment with $3.0 billion of share repurchases in 2024.Increased 2025 premium and service revenues guidance by $4.0 billion driven by Medicaid revenue and better than expected membership performance during the annual enrollment period in Medicare Advantage and PDP.ST. LOUIS, Feb. 4, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today its financial results for the fourth quarter and year ended December

      2/4/25 6:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Asher Andrew Lynn covered exercise/tax liability with 10,566 shares, decreasing direct ownership by 2% to 657,642 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      4/28/25 6:32:31 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Corporate Controller & CAO Casso Katie covered exercise/tax liability with 2,077 shares, decreasing direct ownership by 2% to 96,335 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      4/21/25 5:50:08 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Chief People Officer Mcnally Tanya M covered exercise/tax liability with 964 shares, decreasing direct ownership by 2% to 59,494 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      4/16/25 4:43:24 PM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    SEC Filings

    See more

    $CNC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Centene Corporation filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CENTENE CORP (0001071739) (Filer)

      5/5/25 9:05:53 PM ET
      $CNC
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Centene Corporation

      10-Q - CENTENE CORP (0001071739) (Filer)

      4/24/25 8:18:11 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CENTENE CORP (0001071739) (Filer)

      4/24/25 8:19:02 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene upgraded by Jefferies with a new price target

      Jefferies upgraded Centene from Underperform to Hold and set a new price target of $64.00

      4/8/25 9:08:11 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene downgraded by Argus

      Argus downgraded Centene from Buy to Hold

      2/6/25 7:52:15 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Analyst resumed coverage on Centene with a new price target

      Analyst resumed coverage of Centene with a rating of Overweight and set a new price target of $75.00 from $80.00 previously

      12/17/24 7:34:22 AM ET
      $CNC
      Medical Specialities
      Health Care